|
⚲
|
| Keyboard |
| Decheng Capital LLC
✚
|
|
|---|---|
| CRD # | 293073 |
| SEC # | 801-118587 |
| CIK # | 0002010850 |
| AUM | 2,728.2 M (2026-03-31) |
| Employees | 23 (57% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 650-382-5514 |
| Address | 3000 Sand Hill Road Menlo Park, CA 94025 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($B) |
|---|
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Fees and Compensation A. As an SEC registered investment adviser which provides services to private funds that exclusively accept “Qualified Purchasers,” as defined by the Investment Company Act, DC Global is not required to disclose its specific compensation terms in this Sub-Item. B. The Funds pay the Firm an annual management fee, which is prorated and directly deducted from the Funds each quarter. The calculation of the management fee for Decheng Capital China Life Sciences USD Fund I, L.P, Decheng Capital China Life Sciences USD Fund II, L.P, Decheng Capital China Life Sciences USD Fund III, L.P, Decheng Capital Global Life Sciences Fund IV, L.P., Decheng Capital Global Life Sciences Fund V, L.P., Decheng Capital Global Life Sciences Fund V-A, L.P., and Decheng Capital Global Life Sciences Fund V-B, L.P. are (i) based on a percentage of commitments to the fund from the first year to the fifth year of investment, (ii) based on a percentage of cost of remaining investments for the sixth through tenth years, and (iii) reduced to zero after ten years. For Decheng Global Healthcare Fund (Master), LP, management fees are based on the percent of account balance, which includes valuation of the portfolio. C. The Funds bear all costs of organization and operation, including all trading costs and expenses (e.g., brokerage commissions, transaction fees, spreads, custody, taxes, interest and borrowing costs, clearing, and settlement charges), and all ongoing legal, accounting, tax, bookkeeping, professional, expert and consulting fees and expenses (including the fees and expenses of the directors, the administrator, attorneys and compliance consultants (with certain limitation) for the General Partners and DC Global, research consultants, research- related fees and expenses (including certain travel expenses), portfolio and risk management systems, and quotation services and related equipment), and each Fund’s proportionate share of its costs and expenses. The Funds also pay some or all of these expenses on their behalves and allocate them among the relevant capital accounts. D. The General Partners and DC Global generally bear their own operating, general, administrative and overhead costs and expenses, other than the expenses described above. More information related to expense allocations can be found in the Funds’ Governing Documents. E. The management fee is paid in advance. With respect to the venture capital funds, carried interest is paid to General Partners in arrears upon the disposition of a portfolio asset. Prospectively, funds with a public market mandate will pay to their General Partner or DC Global an annual performance-based fee in arrears, subject to any relevant high-water marks and hurdle rates of return. F. Except as otherwise disclosed, neither the Firm nor any of its supervised persons receive, directly or indirectly, any compensation from the sale of securities or other investment products. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Types of Clients
The Firm provides investment advisory services to pooled investment vehicles that are excepted from
the definition of investment company pursuant to Section 3(c)(7) under the Investment Company Act. As
disclosed in other areas of this Brochure, investment in the Funds is only available to Qualified Purchasers and
the minimum initial commitment is $5 million. |
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| CG Oncology Inc | 431.2 | ||
| Panacea Acquisition Corp | 111.3 | ||
| Upstream Bio Inc | 24.5 | ||
| Aclaris Therapeutics Inc | 15.2 | ||
| Aardvark Therapeutics Inc | 14.8 | ||
| Lyell Immunopharma Inc | 13.9 | ||
| Newamsterdam Pharma Co NV | 10.4 | ||
| Arcus Biosciences Inc | 10.3 | ||
| Revolution Medicines Inc | 9.1 | ||
| Equillium Inc | 8.9 | ||
| View All | |||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| VC | Decheng Capital Global Life Sciences Fund V-A LP | [2025-03-31] | 452.0 M | 32.9 M |
| Offered $700,000,000 · Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $248,000,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Decheng Capital Global Life Sciences Fund V-B LP | [2025-03-31] | 452.0 M | 22.0 M |
| Offered $700,000,000 · Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $248,000,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Decheng Capital Global Life Sciences Fund V LP | [2025-03-31] | 452.0 M | 449.3 M |
| Offered $700,000,000 · Filed 2025-10-03 (D/A) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $248,000,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| HF | Decheng Capital Global Healthcare Fund Master LP | [2021-03-31] | 139.0 M | 228.2 M |
| Filed 2025-10-28 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $5,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| VC | Decheng Capital Global Life Sciences Fund IV LP | [2021-03-31] | 825.3 M | |
| Offered $650,000,000 · Filed 2020-12-15 (D) · Exemption 506(b), 3(c), 3(c)(1), 3(c)(7) · Remaining $650,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Decheng Capital China Life Sciences USD Fund III LP | [2018-07-19] | 625.9 M | |
| Offered $450,000,000 · Filed 2018-04-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $450,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Decheng Capital China Life Sciences USD Fund II LP | [2018-07-19] | 480.6 M | |
| Offered $250,000,000 · Filed 2015-08-17 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining $250,000,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Decheng Capital China Life Sciences USD Fund I LP | [2018-07-19] | 123.0 M | 78.9 M |
| Offered $125,000,000 · Filed 2013-06-05 (D/A) · Exemption 506, 3(c), 3(c)(7) · Remaining $1,998,247 · Duration More than one year · Revenue Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 10 | 2.7 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 10 | 2.7 |
| By Discretionary | ||
| Discretionary | 10 | 2.7 |
| Non-Discretionary | 0 | 0.0 |
| Total | 10 | 2.7 |
| By Non-United States Persons | ||
| Non-United States Persons | 2.6 | |
| United States Persons | 0.2 | |
| Total | 10 | 2.7 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Xiangmin Cui | Director, Executive Officer, Promoter | 14 | 2 | |
| Bay City Capital LLC | Director | 2 | 2 | |
| Decheng Capital SV LLC | Executive Officer | 2 | 2 | |
| Decheng Capital Global Healthcare GP LLC | Executive Officer | 2 | 2 | |
| Decheng Capital Management IV Cayman LLC | Promoter | 1 | 1 | |
| Yuheng Qiu | Director | 1 | 1 | |
| DT Capital Management Company Limited | Director | 1 | 1 | |
| Fengying Yu | Promoter | 1 | 1 | |
| Decheng Capital China Management I Cayman LLC | Promoter | 1 | 1 | |
| Xiangmin Min | Director | 1 | 1 | |
| Decheng Capital Management II Cayman LLC | Promoter | 1 | 1 | |
| Decheng Capital Management III Cayman LLC | Promoter | 1 | 1 | |
| Decheng Capital Management V Cayman LLC | Promoter | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0002010850] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund |
| Comparable Firms | State | AUM |
|---|---|---|
|
Pointer Management LLC
✚
|
TN | 2,790.9 M |
|
Serone Capital Management LLP
✚
|
2,731.1 M | |
|
Sound Point Commercial Real Estate Finance LLC
✚
|
NY | 2,723.4 M |
|
Mangrove Partners IM LLC
✚
|
CT | 2,705.9 M |
|
1Sharpe Capital LLC
✚
|
CA | 2,700.3 M |
|
Hook Mill Capital Partners LP
✚
|
NY | 2,698.0 M |
|
Advanced Portfolio Management LLC
✚
|
NY | 2,697.1 M |
|
Gobi Capital LLC
✚
|
CA | 2,689.4 M |
|
Cadian Capital Management LP
✚
|
NY | 2,680.0 M |
|
Eversept Partners LP
✚
|
NY | 2,651.0 M |